Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, +617

The Lancet Oncology

5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials +8

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes, +27

The Lancet Oncology

Breast OncologyHealth SciencesMedicineClinical TrialsImmune Checkpoint Inhibitor +7

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

David Cameron, Julia Brown, Rebecca Dent, +22

The Lancet Oncology

Adjuvant Bevacizumab-containing TherapyBreast OncologyMedicinePrimary ResultsImmunology +5

Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule

José Baselga, Xavier Carbonell, Noel-Jaime Castañeda-Soto, +6

Journal of Clinical Oncology

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

Andreas Schneeweiß, Stephen Chia, Tamas Hickish, +6

European Journal of Cancer

Breast OncologyOncologySafety StudyBreast CancerPharmacotherapy +5

Effect of Pregnancy on Overall Survival After the Diagnosis of Early-Stage Breast Cancer

Shari Gelber, Alan S. Coates, Aron Goldhirsch, +7

Journal of Clinical Oncology

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

Vernon Harvey, Henning T. Mouridsen, Erik Jakobsen, +4

Journal of Clinical Oncology

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

Martin R. Stockler, Vernon Harvey, Prudence A. Francis, +16

Journal of Clinical Oncology

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Heikki Joensuu, Judith Fraser, Hans Wildiers, +20

JAMA Oncology

Overall survival from breast cancer in women pregnant or lactating at or after diagnosis

Anne Lethaby, Michele A. O'Neill, Barbara H. Mason, +2

International Journal of Cancer